7-(3-chlorophenyl)-9-[(4-chlorophenyl)-1 H-imidazol-1-ylmethyl]-2,3-dihydro-1H,5H-benzo[ij]quinolizin-5-one | 213389-21-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 7-(3-chlorophenyl)-9-[(4-chlorophenyl)-1 H-imidazol-1-ylmethyl]-2,3-dihydro-1H,5H-benzo[ij]quinolizin-5-one
• 英文别名: 4-(3-Chlorophenyl)-7-[(4-chlorophenyl)-imidazol-1-ylmethyl]-1-azatricyclo[7.3.1.05,13]trideca-3,5,7,9(13)-tetraen-2-one
• CAS: 213389-21-0
• 化学式: C₂₈H₂₁Cl₂N₃O
• 分子量: 486.4
• InChiKey: ZMHSZUPSHKAYRM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  34
• 可旋转键数：
  4
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  38.1
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
  申请人：——

  公开号：US20020049327A1

  公开（公告）日：2002-04-25

  This invention concerns compounds of formula 1 the pharmaceutically acceptable acid addition salts and the stereochemically isomeric forms thereof, wherein the dotted line represents an optional bond; X is oxygen or sulfur; -A- is a bivalent radical of formula; R 1 and R 2 each independently are hydrogen, hydroxy, halo, cyano, C 1-6 alkyl, trihalomethyl, trihalomethoxy, C 2-6 alkenyl, C 1-6 alkyloxy, hydroxyC 1-6 alkyloxy, C 1-6 alkyloxyC 1-6 alkyloxy, C 1-6 alkyloxycarbonyl, aminoC 1-6 alkyloxy, mono- or di(C 1-6 alkyl)aminoC 1-6 alkyloxy, Ar, Ar—C 1-6 alkyl, Ar-oxy, Ar—C 1-6 alkyloxy; or when on adjacent positions R 1 and R 2 taken together may form a bivalent radical; R 3 and R 4 each independently are hydrogen, halo, cyano, C 1-6 alkyl, C 1-6 alkyloxy, Ar-oxy, C 1-6 alkylthio, di(C 1-6 alkyl)amino, trihalomethyl, trihalomethoxy, or when on adjacent positions R 3 and R 4 taken together may form a bivalent radical; R 5 is an imidazolyl substituted with hydrogen or C 1-6 alkyl; R 6 hydrogen, hydroxy, halo, cyano, optionally substituted C 1-6 alkyl, C 1-6 alkyloxycarbonyl or Ar; or a radical of formula —O—R 7 , —S—R 8 , —N—R 8 R 9 ; and Ar is optionally substituted phenyl; having farnesyl transferase inhibiting activity; their preparation, compositions containing them and their use as a medicine.

  本发明涉及公式1的化合物及其药物可接受的酸盐和立体化学异构体，其中虚线表示可选键；X是氧或硫；-A-是公式的二价基团；R1和R2各自独立地是氢、羟基、卤、氰、C1-6烷基、三卤甲基、三卤甲氧基、C2-6烯基、C1-6烷氧基、羟基C1-6烷氧基、C1-6烷氧基C1-6烷氧基、C1-6烷氧羰基、氨基C1-6烷氧基、单烷基或二烷基氨基C1-6烷氧基、Ar、Ar-C1-6烷基、Ar-oxy、Ar-C1-6烷氧基；或当相邻位置的R1和R2一起形成二价基团时；R3和R4各自独立地是氢、卤、氰、C1-6烷基、C1-6烷氧基、Ar-oxy、C1-6烷硫基、二(C1-6烷基)氨基、三卤甲基、三卤甲氧基；或当相邻位置的R3和R4一起形成二价基团时；R5是氢或C1-6烷基取代的咪唑基；R6是氢、羟基、卤、氰、可选取代的C1-6烷基、C1-6烷氧羰基或Ar；或公式-O-R7、-S-R8、-N-R8R9的基团；Ar是可选取代的苯基；具有法尼酰转移酶抑制活性；它们的制备、含有它们的组合物以及它们作为药物的用途。
• Methods for assessing and treating leukemia
  申请人：——

  公开号：US20040110792A1

  公开（公告）日：2004-06-10

  Methods for treating leukemia patients include analyzing gene expression profiles of a patient to determine whether the patient is likely to respond to treatment with farnesyl transferase inhibitor (FTI) and, optionally, other therapeutics. The methods are also useful for monitoring patient therapy and for selecting a course of therapy. Genes modulated in response to FTI treatment are provided and are used in formulating the profiles.

  治疗白血病患者的方法包括分析病人的基因表达谱，以确定病人是否可能对法尼酰转移酶抑制剂（FTI）和其他治疗方法有反应。该方法还可用于监测患者治疗和选择治疗方案。提供了对FTI治疗反应调节的基因，并用于制定表达谱。
• Methods for assessing and treating cancer
  申请人：Veridex, LLC

  公开号：EP1502962A2

  公开（公告）日：2005-02-02

  Methods for treating cancer, and preferably hematological malignancy, patients include analyzing gene expression profiles and/or molecular markers of a patient to determine whether the patient is likely to respond to treatment with farnesyl transferase inhibitor (FTI) and, optionally, other therapeutics. The methods are also useful for monitoring patient therapy and for selecting a course of therapy. Genes modulated in response to FTI treatment are provided and are used in formulating the profiles.

  治疗癌症（最好是血液恶性肿瘤）患者的方法包括分析患者的基因表达谱和/或分子标记物，以确定患者是否有可能对法尼基转移酶抑制剂（FTI）以及可选的其他疗法产生反应。这些方法还可用于监测患者的治疗情况和选择疗程。提供了对 FTI 治疗有反应的基因调控，这些基因调控可用于制定概况。
• FARNESYL TRANSFERASE INHIBITING 1,8-ANNELATED QUINOLINONE DERIVATIVES SUBSTITUTED WITH N- OR C-LINKED IMIDAZOLES
  申请人：JANSSEN PHARMACEUTICA N.V.

  公开号：EP0970079B1

  公开（公告）日：2003-10-01
• METHODS FOR ASSESSING ACUTE MYELOID LEUKEMIA
  申请人：ORTHO-CLINICAL DIAGNOSTICS, INC.

  公开号：EP1478773B1

  公开（公告）日：2007-09-19